

The Manager Company Announcements Office ASX Ltd

19 January 2016

Dear Sir,

#### **Lapsing of Options**

**Elemental Minerals Limited** (the 'Company') advises that 78,911,086 listed options (ELMO) exercisable at \$0.25 and 500,000 unlisted options exercisable at \$1.09 have lapsed due to their expiry date.

Please find attached an Appendix 3B in relation to the exercise of 4,843 listed options (ELMO).

Yours sincerely,

**Leonard Math** 

**Director and Joint Company Secretary** 

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced  $o_1/o_7/96$  Origin: Appendix 5 Amended  $o_1/o_7/98$ ,  $o_1/o_9/99$ ,  $o_1/o_7/o_0$ ,  $o_3/o_9/o_1$ ,  $o_1/o_3/o_2$ ,  $o_1/o_1/o_3$ ,  $o_2/o_3/o_3$ 

Name of entity			
Elem	ental Minerals Limited		
ABN	066 422		
31 100	000 422		
We (t	he entity) give ASX the following	g information.	
	1 - All issues ust complete the relevant sections (attac	h sheets if there is not enough space).	
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	Fully Paid Ordinary Shares	
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	4,843	
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully Paid Ordinary Shares	

10271611/1

<sup>+</sup> See chapter 19 for defined terms.

Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  the date from which they do  the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
Issue price or consideration	\$0.25 each
Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Exercise of listed options (ELMO)
Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	No
The date the security holder resolution under rule 7.1A was passed	N/A
Number of *securities issued	N/A
without security holder approval under rule 7.1	- 1/
Number of +securities issued	N/A
with security holder approval under rule 7.1A	
icc Ir • • I H(ti Ith Iisc Tr F Nyu Ny	an all respects from the +issue date with an existing +class of quoted +securities?  If the additional +securities do not rank equally, please state:  If the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  If the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment  Sue price or consideration  Purpose of the issue (If issued as consideration for the acquisition of assets, clearly dentify those assets)  If the entity an +eligible entity that has obtained security nolder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i  The date the security holder resolution under rule 7.1A was bassed  Number of +securities issued without security holder approval under rule 7.1

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer below	
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	19 January 2016	
		[x ]	Lat
		Number	<sup>+</sup> Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	410,280,720	Ordinary fully paid shares

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (*including* the \*securities in section 2 if applicable)

	T . ==
Number	+Class
300,000	Unlisted Options exercisable at \$1.29 expiring 13 February 2016.
250,000	Unlisted Options exercisable at \$1.12 expiring 23 April 2016.
500,000	Unlisted Options exercisable at \$1.18 expiring 1 April 2016.
250,000	Unlisted Options exercisable at \$0.90 expiring 22 May 2017.
6,691,226	Unlisted Options exercisable at \$0.33 expiring 15 April 2018
1,500,000	Unlisted Options exercisable at \$0.33 expiring 26 June 2018
3,500,000	Class B Performance Rights (Dir)
3,500,000	Class C Performance Rights (Dir)
2,666,090	Class A Performance Rights (Emp)
2,666,090	Class B Performance Rights (Emp)
2,666,090	Class C Performance Rights (Emp)

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			

### Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?
12	Is the issue renounceable or non-renounceable?
13	Ratio in which the *securities will be offered
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates
15	<sup>+</sup> Record date to determine entitlements
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
17	Policy for deciding entitlements in relation to fractions
18	Names of countries in which the entity has security holders who will not be sent new offer documents
	Note: Security holders must be told how their entitlements are to be dealt with.
	Cross reference: rule 7.7.
19	Closing date for receipt of

10271611/1

<sup>+</sup> See chapter 19 for defined terms.

	_	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
	_	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
	_	
25	If the issue is contingent on +security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and will be sent to persons entitled	
	_	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
	5 . 1 . 1 . 11 . 40	
28	Date rights trading will begin (if applicable)	
	·	
29	Date rights trading will end (if applicable)	
	_	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

33	<sup>+</sup> Issue	date
	•	uotation of securities complete this section if you are applying for quotation of securities
34	Type (tick o	of securities one)
(a)		+Securities described in Part 1
(b)		All other *securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
<b>Addi</b> Tick to	<b>tional</b>	t have ticked box 34(a)  securities forming a new class of securities  e you are providing the information or
docum 35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36		If the *securities are *equity securities, a distribution schedule of the additiona *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37		A copy of any trust deed for the additional *securities

<sup>+</sup> See chapter 19 for defined terms.

#### Entities that have ticked box 34(b) 38 Number of \*securities for which <sup>+</sup>quotation is sought Class of \*securities for which 39 quotation is sought Do the \*securities rank equally in 40 all respects from the +issue with an existing +class of quoted \*securities? If the additional +securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, interest distribution or payment Reason for request for quotation 41 now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another \*security, clearly identify that other \*security)

Number and \*class of all \*securities quoted on ASX (including the \*securities in clause 38)

Number	<sup>+</sup> Class

10271611/1

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 19 January 2016

(Director & Joint Company secretary)

Print name: Leonard Math

== == == ==

10271611/1

<sup>+</sup> See chapter 19 for defined terms.

### Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for †eligible entities

Introduced 01/08/12. Amended 04/03/13

### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	381,850,877	
Add the following:		
Number of fully paid +ordinary securities	3,500,000	
issued in that 12 month period under an exception in rule 7.2	4,843	
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval		
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	-	
"A"	385,355,720	

10271611/1

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"				
"B"	0.15			
	[Note: this value cannot be changed]			
Multiply "A" by 0.15	57,803,358			
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used				
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	24,925,000			
• Under an exception in rule 7.2				
• Under rule 7.1A				
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>				
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>				
"C"	24,925,000			
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1				
"A" x 0.15	57,803,358			
Note: number must be same as shown in Step 2				
Subtract "C"	24,925,000			
Note: number must be same as shown in Step 3				
<i>Total</i> ["A" x 0.15] – "C"	32,878,358 [Note: this is the remaining placement capacity under rule 7.1]			

<sup>+</sup> See chapter 19 for defined terms.

### Part 2 – NOT APPLICABLE

10271611/1

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.